Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 21817952)

1.

Evolution of laboratory values in patients with Kawasaki disease.

Tremoulet AH, Jain S, Chandrasekar D, Sun X, Sato Y, Burns JC.

Pediatr Infect Dis J. 2011 Dec;30(12):1022-6. doi: 10.1097/INF.0b013e31822d4f56.

2.

[Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].

Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.

Zhonghua Er Ke Za Zhi. 2006 Dec;44(12):891-5. Chinese.

PMID:
17254453
3.

Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.

Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.

Lancet. 2014 May 17;383(9930):1731-8. doi: 10.1016/S0140-6736(13)62298-9. Epub 2014 Feb 24.

PMID:
24572997
4.

Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.

Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.

Pediatr Infect Dis J. 2008 Feb;27(2):155-60. doi: 10.1097/INF.0b013e31815922b5.

PMID:
18174868
5.

Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.

Tse SM, Silverman ED, McCrindle BW, Yeung RS.

J Pediatr. 2002 Apr;140(4):450-5.

PMID:
12006960
6.

Clinical features of recurrent Kawasaki disease and its risk factors.

Yang HM, Du ZD, Fu PP.

Eur J Pediatr. 2013 Dec;172(12):1641-7. doi: 10.1007/s00431-013-2101-9. Epub 2013 Jul 26.

PMID:
23887608
7.

Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.

Burns JC, Song Y, Bujold M, Shimizu C, Kanegaye JT, Tremoulet AH, Franco A.

Clin Exp Immunol. 2013 Dec;174(3):337-44. doi: 10.1111/cei.12182.

8.

[Changes of P-selectin and E-selectin in children with Kawasaki disease].

Qiu Y, Wu J, Fang XY, Lin Z, Wu BY, Cai RY, Xu XY, Zheng H.

Zhonghua Er Ke Za Zhi. 2004 Sep;42(9):688-92. Chinese.

PMID:
15482673
9.

Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease.

Honkanen VE, McCrindle BW, Laxer RM, Feldman BM, Schneider R, Silverman ED.

Pediatr Cardiol. 2003 Mar-Apr;24(2):122-6. Epub 2002 Dec 4.

PMID:
12457252
10.

Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.

Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S.

J Rheumatol. 2012 Apr;39(4):864-7. doi: 10.3899/jrheum.110877. Epub 2012 Feb 15.

PMID:
22337241
11.

Gene-expression patterns reveal underlying biological processes in Kawasaki disease.

Popper SJ, Shimizu C, Shike H, Kanegaye JT, Newburger JW, Sundel RP, Brown PO, Burns JC, Relman DA.

Genome Biol. 2007;8(12):R261.

12.

Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.

Qin L, Saumu MT, Wang H, Shi H, Hu X, Cheng P.

J Huazhong Univ Sci Technolog Med Sci. 2005;25(3):348-50, 370.

PMID:
16201293
13.

Ulinastatin therapy in kawasaki disease.

Iwashima S, Seguchi M, Matubayashi T, Ohzeki T.

Clin Drug Investig. 2007;27(10):691-6.

PMID:
17803344
14.

Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.

Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A.

Circulation. 2006 Jun 6;113(22):2606-12. Epub 2006 May 30.

15.

Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.

Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, Hara J.

J Pediatr. 2000 Aug;137(2):172-6.

PMID:
10931407
16.

Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease.

Yellen ES, Gauvreau K, Takahashi M, Burns JC, Shulman S, Baker AL, Innocentini N, Zambetti C, Pancheri JM, Ostrow A, Frazer JR, Sundel RP, Fulton DR, Newburger JW.

Pediatrics. 2010 Feb;125(2):e234-41. doi: 10.1542/peds.2009-0606. Epub 2010 Jan 25.

17.

Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.

Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.

Pediatrics. 2004 Dec;114(6):e689-93. Epub 2004 Nov 15.

PMID:
15545617
18.

Resistance to intravenous immunoglobulin in children with Kawasaki disease.

Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, Martin DD, Newburger JW, Burns JC.

J Pediatr. 2008 Jul;153(1):117-21. doi: 10.1016/j.jpeds.2007.12.021. Epub 2008 Mar 4.

19.

Comparison of the laboratory data between Kawasaki disease and enterovirus after intravenous immunoglobulin treatment.

Lin LY, Yang TH, Lin YJ, Yu HR, Yang KD, Huang YC, Chang WC, Kuo HC.

Pediatr Cardiol. 2012 Dec;33(8):1269-74. doi: 10.1007/s00246-012-0293-9. Epub 2012 Mar 25.

PMID:
22447381
20.

Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.

Sato S, Kawashima H, Kashiwagi Y, Hoshika A.

Int J Rheum Dis. 2013 Apr;16(2):168-72. doi: 10.1111/1756-185X.12082.

PMID:
23773640
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk